

Bioactive Molecules Isolated for the First Time from *Hyoscyamus albus* L. and their Mechanisms Underlying the Anticancer Effects

Authors : Benhouda Afaf, Yahia Massinissa, Paolo Grieco

Abstract : *Hyoscyamus albus* L. is a small genus from Solanaceae family known by its use in old traditional medicine in the east of Algeria. Aim: This study aimed to characterize bioactive molecules from *H. albus*, evaluate their anticancer activity in several cancer cells and investigate their possible molecular mechanism. Materials and Methods: Different compounds (Peak h of fraction F), (Peak 3 of Fraction F), (Peak 1 of fraction C) were isolated from *H.albus* L by using high-performance chromatography (HPLC), mass spectrometry (MS) and proton NMR (NMR H1). All isolated compounds were subjected to cytotoxicity and antiproliferative assays against a panel of the four cell lines: DU-145, U-2 OS, U-87 MG and LN-229 cell lines and were determined using MTT assay, Annexin V and propodium iodide were used to evaluate apoptosis. Results: The phytochemical study of *H. albus* Fractions led to the isolation of quercetin-3-O- β -dglucopyranosyl-(1 \rightarrow 6)- β -d-glucopyranosid, N-trans-feruloyltyramine, Hydrocaffeoyl-N8- caffeoylspermidine. The biological results indicated that all cell lines were consistently sensitive to P1 FC in a dose-dependent manner. This difference in cytotoxic sensitivity was more pronounced in osteosarcoma cell line, U-2 OS, when compared to prostate cancer and U-87 MG. Cell viability data also demonstrated that only U-87 MG cells were responsive to treatment with Ph FF. compounds P1 FC and Ph FF have induced necrosis and apoptosis in a large part of LN-229 cells. Conclusion: The overall results of the present study provided evidence that isolated compounds are potential therapeutic entities against cancer.

Keywords : *hyoscyamus albus*, cancer cells, compounds, HPLC

Conference Title : ICBBS 2025 : International Conference on Biotechnology and Biological Sciences

Conference Location : Rome, Italy

Conference Dates : January 16-17, 2025